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Introduction
Cure rates for childhood acute lymphoblastic leukemia (ALL) have approached 90% with therapeutic advances over the last several decades. [1] [2] [3] [4] [5] [6] Intensification of therapy with glucocorticoids has played a crucial role in achieving these outcomes. However, one of the most common therapy-related and dose-limiting toxicities of therapy in children with ALL is glucocorticoid-induced osteonecrosis, particularly in those greater than 10 years of age. The majority of symptomatic cases of osteonecrosis occur within the first two years of treatment, 7, 8 often precipitating early withdrawal of glucocorticoids from therapy for ALL.
The incidence of glucocorticoid-induced osteonecrosis varies widely. 7, 9 Age remains the most significant risk factor, with symptomatic osteonecrosis (defined as grade 2-4) occurring in 10-30% of children greater than 10 years of age. 7, 8, [10] [11] [12] Glucocorticoid-induced osteonecrosis also complicates treatment of non-malignant conditions such as solid organ transplant and arthritis. [13] [14] [15] Osteonecrosis can result in debilitation and adversely affect quality of life, often requiring surgical intervention.
In this study, we conducted the largest genome-wide association study (GWAS) to date of glucocorticoid-induced osteonecrosis, with replication cohorts including not only children treated for ALL 7 but also adults and children treated with glucocorticoids for other medical conditions.
Our goal was to identify germline genetic variants that predispose to glucocorticoid-induced osteonecrosis.
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Methods

Subjects
The discovery cohort included children with newly diagnosed ALL with germline DNA available who were treated on the Children's Oncology Group (COG) AALL0232 protocol (NCT00075725, CONSORT Diagram) for high risk B-precursor ALL (n = 2285) ( Table 1) (Supplemental Figures S1 and Table S1 ). Validation cohorts included children with newly diagnosed ALL treated on the St. Jude Total XV protocol (NCT00137111, CONSORT Diagram) (n = 361) 7 (Supplemental Figure S1 and Table S2 ), and a separate cohort comprising children and adults treated with corticosteroids in the Vanderbilt University Medical Center Biorepository
BioVU database 16 (n = 309) (Table 1 ) (Supplemental Figure S1 and Table S3 ). Patients included in the genetic association analyses represented 80% (n = 2285 of 2868) of participants on the COG AALL0232 protocol, and 73% (n = 361 of 498) of patients on the St. Jude Total XV protocol (Supplemental Figure S1 ).
Informed consent was obtained from patients 18 years and above, and from parents or guardians for patients under the age of 18 in accordance with the Declaration of Helsinki. The COG AALL0232 protocol was approved by the National Cancer Institute and the institutional review boards of participating institutions, and the St. Jude Total XV trial was approved by the St. Jude
Institutional Review Board.
The second validation cohort for this study was derived from BioVU, Vanderbilt's repository linking DNA from remnant blood samples to de-identified electronic medical record data. 17 Due to de-identification, use of this resource qualifies as non-human subjects research. IRB
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From 6 performed using the 1000 Genomes Project (http://www.1000genomes.org/) database as the reference genome, leveraging linkage disequilibrium (LD) within racial ethnic groups (Northern European ancestry, West African ancestry, other) with MaCH-Admix software (University of North Carolina) for the COG AALL0232 and St. Jude Total XV cohorts, and IMPUTE2 (University of Oxford) for the Vanderbilt cohort. For the imputation, reference groups for imputing SNPs in patients classified as white (see below) were the European individuals in 1000
Genomes, for patients classified as black were the 1000 Genomes Africans, and for the remaining patients were all individuals in the 1000 Genomes database.
Genetic Ancestry Race Classification
Genetic ancestry for each patient was determined using STRUCTURE (version 2.2.3). 21 When ancestry was assessed as a categorical variable, individuals were classified as white, black,
Hispanic and Asian based on percentage inferred genetic ancestry as follows: >90% Northern
European (CEU) were classified as white; >70% West African (YRI) classified as black; >90%
East Asian (CHB/JPT) classified as Asian; those with Native American ancestry >10% and greater than the % West African ancestry were classified as Hispanic. Patients not falling into these groups were categorized as Other.
Quality control
Identical quality control measures were enforced for the discovery and validation cohorts. All
SNPs with a call rate <95% were excluded. SNPs with a minor allele frequency (MAF) greater than 1% but deviating from Hardy-Weinberg equilibrium within Europeans (P < 0.0001) were also excluded. Otherwise, no MAF threshold was enforced.
Statistical analyses
For personal use only. on April 14, 2017. by guest www.bloodjournal.org From For the discovery GWAS, SNP genotypes were compared in 250 ALL osteonecrosis cases and 2035 controls enrolled on COG AALL0232. Adjusting for gender, age, % ancestry as a continuous variable, and treatment (see Supplementary Materials Methods for details on consideration of treatment variables), association of genotypes with ON was tested with a Cox proportional hazard model for time dependent analyses and logistic regression for time independent analyses. For the time independent analyses, only patients with a follow up time of 800 days or greater from the start of therapy on COG AALL0232 were included in the analysis.
Results from analyses with imputed SNPs and each independent platform were merged and rank ordered by P value. Analyses were performed using R software (version 3.0; www.r-project.org).
We excluded rare/low frequency SNPs (MAF < 0.1) with a protective, negative correlation with osteonecrosis risk (odds ratio < 1).
Time independent analyses were performed using a logistic regression model in the two validation cohorts: 68 osteonecrosis cases and 293 controls from the St. Jude Total XV cohort as previously published, 7 and 82 cases and 227 controls from the Vanderbilt BioVU cohort. Metaanalysis of the discovery and validation cohorts was performed using Stouffer's Z-score method.
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Pathway and network analyses were performed to identify biological networks enriched within the top ranked SNPs for each of the cohorts using QIAGEN Ingenuity Pathway Analysis (IPA;
www.qiagen.com/ingenuity). Top SNPs were selected with meta-analysis P value cutoffs < 0.0001 or < 0.001 and genes closest to SNPs based on chromosomal location were used for the pathway analyses.
The PheWAS analysis was performed as described, 23, 24 (Supplementary Materials Methods)
for the 137 SNPs within the glutamate receptor signaling pathway genes. We tested for their associations with 1,358 phenotypes using the extant BioVU genotype data linked to electronic health records for over ten thousand individuals.
Results
Covariates included in the GWAS
The overall frequency of symptomatic grade 2-4 osteonecrosis in patients included in the entire Table S1 ) to be associated with a higher risk of osteonecrosis.
African genetic ancestry was associated with a decreased risk of osteonecrosis compared with individuals of European genetic ancestry (HR = 0.19; 95%CI, 0.07-0.51, P = 1.02 x 10 -3 ). Supplemental Table S4) were also included as covariates in the GWAS.
Treatment variables A and B (Supplemental Materials Methods and
As reported previously 7 , the cumulative incidence of symptomatic osteonecrosis grade 2-4 in the St. Jude Total XV cohort was 17.6%, with older age (P = 7.81 x 10 -7 ) and more intensive therapy (P = 9.48 x 10 -3 ) as significant covariates (Supplemental Table S2 ).
GWAS
In the discovery GWAS in the COG AALL0232 cohort, adjusting for gender, age, ancestry and treatment, a variant at 9q31.1 (rs10989692, P = 3.59 x 10 -7 ), ~ 170kb 5' of the GRIN3A locus (glutamate [NMDA] receptor subunit 3A), had the strongest association with osteonecrosis risk in both a time dependent and time independent analysis (Supplemental Tables S5 and S6 
Meta-analysis
Meta-analysis was performed by combining GWAS results from both the discovery cohort and the two validation cohorts. The 9q31.1 locus (near GRIN3A) was the highest ranked region including multiple SNPs in LD with rs10989692 (P = 2.68 x 10 -8 ) (Table 2, Figure 3) . After the 9q31.1 locus, the next highest ranked variant is an intronic SNP rs2154490 in GRIK1 (glutamate receptor, ionotropic, kainate), on chromosome 21 (P = 1.28 x 10 -6 ) (Table 2, Figure 3) . The additional minor A allele at rs2154490 conferred a higher risk of osteonecrosis in all three cohorts: COG AALL0232 (HR = 1.29, P =0.016), St Jude Total XV (OR = 1.86, P =0.0078) and Vanderbilt (OR = 2.13, P = 9.1 x 10 -4 ) (Supplemental Figure S5) .
The top nonsense SNP from the meta-analysis (Supplemental Table S9 
Pathway analysis and PheWAS
Based on the meta-analysis, there were 197 SNPs with P values < 0.0001 which were annotated to 64 genes (Supplemental Table S10 ). Ingenuity Pathway Analysis using these 64 genes (Supplemental Table S11 ) showed that the glutamate receptor signaling pathway, including three genes GRIN3A, GRIK1 and GRM7, was the top canonical pathway (P = 4.8 x 10 -4 ). Using a P value cutoff of 0.001, there were 433 genes, and the glutamate receptor signaling pathway remained the top pathway with additional genes in the pathway including GRM3, GRIK4 and GRIA1 (P = 9.8 x 10 -4 , Supplemental Table S11 ).
All SNPs with P value <0.05 in or near genes within the glutamate pathway found to be significant in at least one of three cohorts were selected for analysis in a PheWAS (see Supplementary Materials) of the Vanderbilt University Medical Center BioVU database to explore whether these same osteonecrosis variants were associated with any of 1358 other phenotypes in the BioVU repository (Supplementary Table S12 ). None of these associations achieved a Bonferroni significance threshold of 3.7x10 -5 . However, among the top five phenotypes associated with SNPs in GRIN3A were diseases of the respiratory tract (OR = 3.02, P = 3.1 x 10 -4 ) and the long term use of antithrombotics within the circulatory system (OR = 2.13, P = 4.7 x 10 -4 ) (Supplementary Table S13 ). Other phenotypes included cerebral ischemia (OR = 1.64, P = 2.5 x 10 -3 ) and arterial embolism and thrombosis (OR = 1.88, P = 4.2 x 10 -3 ).
Discussion
The development of osteonecrosis can result in serious debilitation and requires surgical intervention in many cases. For example, in the Children's Cancer Group 1961 study, 143
patients (of 2056 enrolled) developed symptomatic osteonecrosis at 377 confirmed sites leading to 139 surgeries. 8 Identification of risk factors for the development of osteonecrosis in patients undergoing therapy for ALL might facilitate tailoring therapy to minimize its risk.
In this study, we performed a GWAS which identified a locus at 9q31.1 near GRIN3A as associated with osteonecrosis in both the discovery and validation cohorts, and the second highest ranked variant was in a related gene GRIK1. The same GRIN3A variant was associated in the meta-analysis of the discovery and validation cohorts (P = 2.68 x 10 -8 ), and the glutamate receptor pathway was the top canonical pathway based on the meta-analysis of all three cohorts.
These findings suggest the involvement of the glutamate pathway in the pathogenesis of osteonecrosis not only in childhood ALL, but in a heterogeneous cohort of children and adults who were treated with prolonged corticosteroids for other medical conditions. 30,31 Interestingly, we previously reported that polymorphisms within a third glutamate receptor gene, GRIA1, were the top genomic variants associated with asparaginase allergy in a GWAS of children with ALL in the St. Jude cohort, 32 a finding recently independently replicated. 33 We have also reported that asparaginase allergy was associated with lower systemic exposure to asparaginase, 34 which in turn was associated with a lower risk of osteonecrosis in the St. Jude cohort. 35 This prompted us to evaluate asparaginase allergy in the COG AALL0232 discovery cohort (n=1845 with followup > 800 days), and consistent with the St. Jude cohort, grade 2-4 asparaginase allergy was associated with the risk of osteonecrosis: 206 out of 1,647 (12.5%) for those without and variations in glutamate receptors may contribute to a proximal vascular event that leads to an increased risk of osteonecrosis in individuals exposed to glucocorticoid therapy.
Conclusions
We hypothesize that different mechanisms of glucocorticoid-induced osteonecrosis may predominate among patients, influenced by variation in concurrent drug therapy as well as inherited genetic risk factors. To our knowledge, this is the largest genome-wide investigation of glucocorticoid-induced osteonecrosis. Our findings suggest for the first time a possible association between inherited genetic variations in glutamate receptors and the development of glucocorticoid-induced osteonecrosis in both ALL and non-ALL settings. The ability to identify genetic risk factors for osteonecrosis has implications for understanding the underlying mechanism of this common and serious adverse effect of glucocorticoids, and may have implications for modifying therapy decisions in the future. 
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